The phase 3 KEEPsAKE 2 trial investigated the efficacy and safety of risankizumab versus placebo in patients with active PsA who had previous inadequate response or intolerance to ≤2 biological ...

Phase 2 results with once-weekly dosing of 20mg pelacarsen showed that 98% of patients achieved a reduction in Lp(a) levels that took them below the 50mg/dL threshold considered to be a risk ...

After 24 weeks, those proportions reached 74.1% and 64.9% respectively, with the tolerability profile of the drug consistent with the phase 2 FRONTIER 1 and 2 studies reported last year.